Research briefs: Prolactin implicated in cardiomyopathy

Prolactin-blocking drugs may play a role in reversing or preventing post-partum cardiomyopathy (PPCM), according to US research. Studies in mice showed that those that lacked the gene STAT3, specifically in heart muscle cells, consistently developed PPCM. The researchers then found a similar imbalance in humans. However, prolactin-blocking drugs were found to overcome the heart damage caused by a lack of the gene STAT3. Women with PPCM who were given prolactin-blocking drugs showed an increased heart function and all survived the four-month observation period (Cell Online 2007).

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus